Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-10384
- Development stage
- Phase 2
- Lead developer
- Hansoh BioMedical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HS-10384 is an orally administered small molecule drug under development for the treatment of vasomotor symptoms (VMS), such as hot flashes, in postmenopausal women. It is classified as a Category 1 innovative drug and is being developed primarily in China. The mechanism of action for HS-10384 has not been disclosed or remains undefined. Clinical trials have reached Phase 2 to evaluate its efficacy and safety in menopausal women with moderate to severe vasomotor symptoms. The drug was self-developed by Hansoh Pharmaceutical Group, with clinical trial sponsorship from Shanghai Hansoh Biomedical Co., Ltd., and involvement from Changzhou Hengbang Pharmaceutical Co., Ltd.[1][2][4][7]
Beyond the preview
Go deeper on HS-10384.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-10384.